Opinion
Video
Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024
Author(s):
Saad Z. Usmani, MD, MBA, FACP, discusses how the AQUILA study data presented at ASH 2024, highlighting the benefits of early intervention in high-risk smoldering multiple myeloma, could impact treatment strategies by improving progression-free survival, while also addressing potential drawbacks of intervening too early in the disease course.
Video content above is prompted by the following:
- Coming into ASH 2024, what would did consider to be the largest unmet need in the treatment and management of multiple myeloma?
- Discuss the data presented at the 2024 ASH Annual Meeting from the AQUILA study in high-risk smoldering multiple myeloma. (Abstract)
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Primary end point: progression-free survival, median not reached for daratumumab vs 41.5 for active observation
- What are your key takeaways from this study, and how might this data impact the way high-risk smoldering multiple myeloma is managed?
- What potential drawbacks could arise from intervening this early in the disease course of multiple myeloma?
Related Videos
Related Content
